HBV RNAi must have passed critical safety hurdle | ABUS Message Board Posts

Arbutus Biopharma

  ABUS website

ABUS   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  34738 of 34756  at  11/25/2019 7:51:37 AM  by

Biogiek


HBV RNAi must have passed critical safety hurdle

According to trial registration site, AB-729 has passed the healthy volunteer part of safety (24 of 24 planned accrued across 4 ascending dose levels)

https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=377235&isReview=true

and is therefore on to the HBV patient part 2 of the study that was contingent on HV safety (3 accrued as of the last update: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=377840&isReview=true

Call me boring and talking my book, but this is huge news to this $80M MC company. Taking RNAi efficacy for granted based on all we know about GalNAc and HBV, on-target liver safety is all this is about at this stage of the game.

And who knows, maybe this little $10B deal that happened over the weekend could wake up ABUS Board and mgmt as to the value of 729. Hey, it might even enter Vivek's consciousness.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 256
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...